Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Seres Therapeutics Inc.

    NASDAQ: MCRB · Real-Time Price · USD
    7.12
    -0.01 (-0.14%)
    At close: Jun 05, 2025, 3:59 PM
    7.55
    6.01%
    After-hours: Jun 05, 2025, 05:59 PM EDT

    Seres Therapeutics Statistics

    Share Statistics

    Seres Therapeutics has 8.73M shares outstanding. The number of shares has increased by 0.72% in one year.

    Shares Outstanding

    n/a
    		 8.73M

    Shares Change (YoY)

    n/a
    		 0.72%

    Shares Change (QoQ)

    n/a
    		 0.22%

    Owned by Institutions (%)

    n/a
    		 41.32%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 2,717

    FTD / Avg. Volume

    n/a
    		 3.02%

    Short Selling Information

    The latest short interest is 798.97K, so 9.15% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 798.97K

    Short % of Shares Out

    n/a
    		 9.15%

    Short % of Float

    n/a
    		 14.89%

    Short Ratio (days to cover)

    n/a
    		 7.39

    Valuation Ratios

    The PE ratio is 18990.89 and the forward PE ratio is -0.88. Seres Therapeutics's PEG ratio is -189.72.

    PE Ratio

    n/a
    		 18990.89

    Forward PE

    n/a
    		 -0.88

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 187.37

    P/FCF Ratio

    n/a
    		 -17.34

    PEG Ratio

    n/a
    		 -189.72
    Financial Ratio History

    Enterprise Valuation

    Seres Therapeutics has an Enterprise Value (EV) of 2.64B.

    EV / Sales

    n/a
    		 0

    EV / EBITDA

    n/a
    		 -21.79

    EV / EBIT

    n/a
    		 -17.79

    EV / FCF

    n/a
    		 -17.74

    Financial Position

    The company has a current ratio of 0.94, with a Debt / Equity ratio of 6.65.

    Current Ratio

    n/a
    		 0.94

    Quick Ratio

    n/a
    		 0.94

    Debt / Equity

    n/a
    		 6.65

    Debt / EBITDA

    n/a
    		 -0.76

    Debt / FCF

    n/a
    		 -0.62

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is 0.99% and Return on Invested Capital is 0%.

    Return on Equity

    n/a
    		 0.99%

    Return on Assets

    n/a
    		 0.1%

    Return on Invested Capital

    n/a
    		 0%

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $1,320.39

    Employee Count

    n/a
    		 103

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 136K

    Effective Tax Rate

    n/a
    		 100%

    Stock Price Statistics

    The stock price has increased by -68.77% in the last 52 weeks. The beta is 2.62, so Seres Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.62

    52-Week Price Change

    n/a
    		 -68.77%

    50-Day Moving Average

    n/a
    		 9.55

    200-Day Moving Average

    n/a
    		 14.84

    Relative Strength Index (RSI)

    n/a
    		 40.19

    Average Volume (20 Days)

    n/a
    		 89,896

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -121.31M

    Net Income

    n/a
    		 136K

    EBITDA

    n/a
    		 -121.31M

    EBIT

    n/a
    		 -125.77M

    Earnings Per Share (EPS)

    n/a
    		 0
    Full Income Statement

    Balance Sheet

    The company has 30.79M in cash and 91.64M in debt, giving a net cash position of -60.85M.

    Cash & Cash Equivalents

    n/a
    		 30.79M

    Total Debt

    n/a
    		 91.64M

    Net Cash

    n/a
    		 -60.85M

    Retained Earnings

    n/a
    		 -978.1M

    Total Assets

    n/a
    		 164.18M

    Working Capital

    n/a
    		 34.76M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -148.61M and capital expenditures -380K, giving a free cash flow of -148.99M.

    Operating Cash Flow

    n/a
    		 -148.61M

    Capital Expenditures

    n/a
    		 -380K

    Free Cash Flow

    n/a
    		 -148.99M

    FCF Per Share

    n/a
    		 -0.96
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    MCRB does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 0.01%

    FCF Yield

    n/a
    		 -5.77%
    Dividend Details

    Analyst Forecast

    The average price target for MCRB is $15, which is 110.7% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $15

    Price Target Difference

    n/a
    		 110.7%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 5
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 0.04

    Graham Upside

    n/a
    		 -99.44%

    Stock Splits

    The last stock split was on Apr 22, 2025. It was a backward split with a ratio of 1:20.

    Last Split Date

    n/a
    		 Apr 22, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:20

    Scores

    Altman Z-Score

    n/a
    		 -9.96

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist